The APOL1‑mediated kidney disease market is a niche but strategically important segment within nephrology and rare disease therapeutics. It centers on patients carrying high‑risk APOL1 gene variants, which are strongly associated with faster progression of chronic kidney disease, particularly in populations of African ancestry.
The market was estimated at around USD 0.48 billion in 2023,...
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek